#Singapore #Waltham #AI Imaging #LungVision #Body Vision Medical

Body Vision Medical's LungVision®: A New Era for Lung Cancer Diagnosis in Singapore

In a significant breakthrough for the medical community, Body Vision Medical has announced that its advanced imaging technology, LungVision®, has received Pre-Market Approval from Singapore's Health Sciences Authority (HSA). This approval marks a major milestone in the quest for early detection and diagnosis of lung cancer, which poses a considerable health challenge in Singapore, ranking as the second-most common cancer among men and the third among women.

Lung cancer detection has seen stark statistics in recent years; data from the Singapore Cancer Registry reveals that between 2018 and 2022, approximately 9,000 cases were diagnosed, largely at late stages. Late-stage diagnosis is often associated with diminished treatment efficacy and lower survival rates. The implementation of advanced imaging technologies like LungVision aims to combat these issues, enhancing the prospects for better patient outcomes through early diagnosis.

"Receiving Pre-Market Approval from HSA signifies a pivotal achievement for both physicians and patients in Singapore," stated Benny Krauz, Vice President of Regulatory and Quality at Body Vision Medical. This new platform empowers physicians with enhanced diagnostic tools, improving the success rates of bronchoscopy procedures with real-time three-dimensional imaging. This functionality facilitates a critical advancement in the lung cancer diagnostic process, potentially shifting the stage at which cancer is detected.

LungVision® effectively converts standard two-dimensional fluoroscopic imaging into an AI-powered three-dimensional imaging system. This innovative technology assists medical professionals in navigating and visualizing during procedures more accurately, thus leading to more precise bronchoscopic biopsies. Given that improved early diagnosis is vital for treating pulmonary nodules effectively, LungVision stands to make a substantial difference in lung cancer management, whilst keeping procedural costs manageable.

Daniel Soh, Managing Director for Scanmed Technology, highlighted the significance of this approval. “By introducing LungVision to Singapore, we are enhancing diagnostic accuracy in pulmonary care. This platform aligns with our commitment to delivering high-quality, innovative healthcare solutions, as LungVision facilitates earlier detection and increases biopsy accuracy, which is crucial for patient care in the region.”

Body Vision Medical operates with the vision of globalizing groundbreaking medical technology to save lives, particularly through the operational capabilities provided by LungVision. This system offers AI-driven real-time image guidance, addressing the clinical demands for early and definitive lung cancer diagnoses, thereby enabling effective treatment of lung lesions via minimally invasive procedures.

For those interested in learning more about LungVision or inquiring about its availability in Singapore, additional details can be found on their official website at scanmed.com.sg. For direct inquiries, Daniel Soh can be reached via [email protected]

About Body Vision Medical

Founded with the mission to transform lung cancer diagnosis through advanced imaging technology, Body Vision Medical specializes in AI-powered solutions designed to enhance clinical decision-making and treatment efficiency. Visit bodyvisionmedical.com for more information and connect with them on LinkedIn for updates and insights.

About Scanmed Technology

As a prominent medical solutions provider in Singapore, Scanmed Technology is dedicated to introducing pioneering healthcare technologies to the local market. With deep industry expertise and a focus on clinical excellence, they collaborate with global innovators to deliver transformative solutions that elevate the standard of patient care.